FindMyKOL
Clinical trialNCT00604461TerminatedPhase 1/2Interventional

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

NCT00604461 is a phase 1/2 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. As of 18 Nov 2026, it was terminated. It studies Carboplatin in Mesothelioma. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2007 and a primary completion date of 31 Jan 2011.

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment13Mesothelioma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00604461
FieldValue
Registry IDNCT00604461
StatusTerminated
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorH. Lee Moffitt Cancer Center and Research Institute
Enrollment13
Registered sites1
Countries1
ConditionsMesothelioma
DrugsCarboplatin
Start31 Oct 2007
Primary completion31 Jan 2011
Study completion31 Jan 2011
Last update posted23 Mar 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study was to evaluate how effective the combination of Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients with Malignant Pleural Mesothelioma (MPM). A combination of cisplatin and pemetrexed is considered standard for this disease and typically off protocol patients would receive cisplatin or carboplatin and pemetrexed as standard of care. The planned length of the study (first patient screened to last patient enrolled) was 24 months. The planned length of the entire study (enrollment period + the treatment period + a follow-up period of at least 12 months) was 36 months.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Tawee Tanvetyanon, M.D.

    H. Lee Moffitt Cancer Center and Research Institute

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00604461

Each answer restates registry values shown on this page.

What is NCT00604461?

NCT00604461 is a phase 1/2 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. It studies Carboplatin in Mesothelioma.

Who leads NCT00604461?

The registry names Tawee Tanvetyanon, M.D. (principal investigator, H. Lee Moffitt Cancer Center and Research Institute) as the overall official.

Where does NCT00604461 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00604461 study?

The registered drug and biological interventions are Carboplatin.

When did NCT00604461 end?

The registry lists a primary completion date of 31 Jan 2011 and a study completion date of 31 Jan 2011. The sponsor last updated the record on 23 Mar 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.